Skip to main content

Case study

Generating new data with the Voice-to-Claim® research methodology

To build a fuller picture of burden, the Optum HEOR team uses a proprietary methodology that investigates treatment journey experiences.

Understanding the patient experience through novel data collection

Claims and electronic health records (EHR) frequently tell only part of the story. These gaps in the patient’s journey become even more evident when it comes to socially sensitive conditions or when the most common treatment involves over-the-counter medicines.

Both challenges stood in the way of 2 pharmaceutical companies co-developing a new drug to treat 2 prevalent constipation-related disorders — chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). They needed to better understand the patient burden and any unmet needs.

Generating new data with Voice-to-Claim® research

To build a more complete picture of the patient burden, the Optum® Health Economics and Outcomes Research (HEOR) team uses a proprietary methodology, called Voice-to-Claim® research, that investigates patients’ experiences with their treatment journey through surveys, one-on-one interviews and medical chart abstraction.

The collaboration between Optum and the manufacturers introduced the first real-world, longitudinal research platform in IBS-C and CIC to capture the chronic symptom burden associated with these conditions. The platform enriches available claims data with patient-reported outcomes and provides the researchers with the data to understand the treatment’s full effects — enabling them to ultimately fill unmet needs and improve patient satisfaction.

Related healthcare insights

View all

Article

What’s informing HEOR strategies in 2025?

Discover how Ami Buikema and Rifky Tkatch are helping prepare their clients for next year.

Article

10 years of innovation with the FDA — and more in store

Dr. John Seeger reflects on Optum contributions to the Sentinel Initiative and looks forward to the opportunities ahead.

Article

Reassessing the Inflation Reduction Act with real-world evidence

Cut through the noise of the Inflation Reduction Act of 2022 with key points aimed to help life sciences leaders leverage impactful data.